Portfolio
The OVO Pharmaceuticals product range
11 presentations across research pens and research vials. Each product page contains presentation, storage, route and specification detail.
Research Pens
Multidose prefilled pen presentations with dose selection, cold chain packaging and single patient use design.
GLP 1 receptor agonist
Semaglutide 5 mg
5 mg / 3 ml prefilled pen for subcutaneous use.
View details →
Dual GIP/GLP 1 receptor agonist
Tirzepatide 20 mg
20 mg / 3 ml prefilled pen for subcutaneous use.
View details →
Dual GIP/GLP 1 receptor agonist
Tirzepatide 40 mg
40 mg / 3 ml prefilled pen for subcutaneous use.
View details →
Triple receptor agonist
Retatrutide 20 mg
20 mg / 3 ml prefilled pen for subcutaneous use.
View details →
Triple receptor agonist
Retatrutide 40 mg
40 mg / 3 ml prefilled pen for subcutaneous use.
View details →
Somatropin (recombinant DNA origin)
Ovotropin 72 IU
Somatropin (recombinant DNA origin) 72 IU prefilled pen.
View details →
Blended peptide complex
GLOW 70 mg / 3 ml
70 mg / 3 ml prefilled pen, 23.3 mg/ml.
View details →
Coenzyme
NAD+ 500 mg / 3 ml
500 mg / 3 ml prefilled pen, 166.7 mg/ml.
View details →Research Vials
Lyophilised powder vials supplied with a sodium chloride ampoule for reconstitution before use.
Lyophilised peptide
Retaovotride 20 mg
20 mg lyophilised vial supplied with 0.9% saline ampoule.
View details →
Lyophilised peptide
Retaovotride 40 mg
40 mg lyophilised vial supplied with 0.9% saline ampoule.
View details →
Human chronic gonadotropin
HCG 5000 IU
5000 IU lyophilised vial supplied with 0.9% saline ampoule.
View details →